Associated Genetic Biomarkers
Folliculin (FLCN) is a gene that encodes a protein that functions in the pathogenesis of a rare form of kidney cancer. The protein may also have roles in tumor suppression, colorectal tumorigenesis, and energy/nutrient sensing in certain signaling pathways. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
FLCN is altered in 1.23% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and leiomyosarcoma having the greatest prevalence of alterations .
The most common alterations in FLCN are FLCN Mutation (1.05%), FLCN Amplification (0.24%), FLCN Loss (0.13%), FLCN H429Tfs*39 (0.11%), and FLCN R17H (0.02%) .
FLCN status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain FLCN status as an inclusion criterion, 2 are phase 2 (1 open).
Trials with FLCN status in the inclusion eligibility criteria most commonly target B-cell non-hodgkin lymphoma, malignant solid tumor, and multiple myeloma .
The most frequent alteration to serve as an inclusion eligibility criterion is FLCN Mutation .
Temsirolimus is the most frequent therapy in trials with FLCN as an inclusion criteria .
Significance of FLCN in Diseases
Renal Cell Carcinoma +
Malignant Solid Tumor +
B-Cell Non-Hodgkin Lymphoma +
FLCN is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLCN status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) .
Multiple Myeloma +
FLCN is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FLCN status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.